Insider information: Faron Initiates Phase 2 Part of BEXMAB

MDS patients who have failed prior HMA therapy selected as first indication to advance into Phase 2 3 mg/kg and 6 mg/kg doses selected in accordance with FDA’s Project Optimus initiative guidancePhase 2 part of the study will recruit 32 HMA-failed MDS patients for 1:1 dose randomization with possible data release after 20 patients have received more than two treatment cycles Company announcement, Inside Information TURKU, Finland and BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceutical

Related Keywords

Jukka , Lapland , Finland , Boston , Massachusetts , United States , Helsinki , Eteläuomen Läi , Mary Jane Elliott , Lindsey Neville , Sandy Jamieson , David Daley , Mika Kontro , Markku Jalkanen , Jo Turner , Juha Karttunen , Christopher Golden , Drug Administration , Peel Hunt , Cairn Financial Advisers , Faron Pharmaceuticals Ltd , Helsinki University Hospital Comprehensive Cancer Center , First North , Associate Professor , Principal Investigator , Chief Executive Officer , Project Optimus , Jane Elliott , Certified Adviser , Nasdaq First , Us Food And Drug Administration , Faron Pharmaceuticals , Multicenter Study , Dose Levels , The Company , Standard Of Care , Company ,